Confo Therapeutics Secures Grant for Groundbreaking Research
Confo Therapeutics, a notable player in the field of G-protein coupled receptors (GPCRs), recently announced a significant milestone in its journey towards pioneering new treatments. The company has received a EUR 1 million grant from Flanders Innovation & Entrepreneurship (VLAIO). This financial backing will propel Confo's research into ultra-long-acting medicines that harness the potential of bi- and multi-specific antibody formats.
Advancing the Future of Therapeutics
This two-year grant not only recognizes the innovative capabilities of Confo's proprietary platform but also emphasizes the importance of addressing chronic conditions like obesity and metabolic disorders. Antibody therapeutics developed from this platform are designed to interact with multiple biological pathways, potentially delivering enhanced efficacy for patients.
Leadership Insight on the Grant
Cedric Ververken, the CEO of Confo Therapeutics, expressed optimism regarding this grant, stating it validates the company's innovative technology and showcases their commitment to addressing unmet medical needs in metabolic and endocrine diseases. The funding is expected to significantly enhance their capabilities in developing ultra-long-acting GPCR antibodies, further solidifying their leadership in drug discovery.
Transformative Antibody Development
Christel Menet, CSO of Confo Therapeutics, highlighted the necessity for long-acting therapies that improve pharmacokinetics compared to traditional peptide-based treatments. The support from VLAIO will expedite the creation of novel treatments that offer patients meaningful therapeutic benefits in managing complex conditions.
Innovative Approaches to GPCR Targeting
Confo is recognized for its proprietary platform which facilitates the discovery of both small molecules and antibodies targeting challenging GPCRs. One notable success includes an antibody agonist targeting the melanocortin receptor 4 (MC4R), demonstrating the viability and success of their innovative approaches. The publication of this work in a prestigious journal showcases the rapid advancements within Confo’s portfolio of antibody therapies.
About Confo Therapeutics
Confo Therapeutics is a clinical-stage biotechnology company dedicated to enhancing the therapeutic landscape for metabolic and endocrine diseases through the development of innovative GPCR-targeting medicines. With a mission to transform patient outcomes, Confo is building a robust pipeline aimed at addressing serious health challenges. The company is powered by a team of industry veterans with comprehensive expertise in GPCR-directed drug development, positioning Confo for success in shaping the future healthcare landscape.
Contact Information
For inquiries, please reach out to:
- Confo Therapeutics
Dr. Cedric Ververken, CEO
+32 (0) 9 396 74 00
info@confotherapeutics.com - Trophic Communications
Valeria Fisher
+49 (0) 175 8041816
confo@trophic.eu
Frequently Asked Questions
What is the purpose of the VLAIO grant awarded to Confo Therapeutics?
The grant will support the development of ultra-long-acting antibody therapies targeting GPCRs for metabolic and endocrine conditions.
Who is the CEO of Confo Therapeutics?
The CEO of Confo Therapeutics is Dr. Cedric Ververken, who leads the company in its innovative pursuits.
What role do GPCRs play in drug discovery?
GPCRs are critical targets for drug discovery as they are involved in many physiological processes and are associated with various diseases, making them vital for therapeutic interventions.
How does the proprietary platform of Confo Therapeutics benefit its research?
The platform allows for the successful discovery and development of targeted therapies, enhancing drug efficacy and addressing complex medical needs.
What types of therapies are being developed by Confo Therapeutics?
Confo Therapeutics is developing bi- and multi-specific antibody therapies aimed at treating conditions like obesity and various metabolic disorders.
